CKD Bio Corp.
Price Chart
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 84.15B KRW |
| Revenue | 158.24B KRW |
| Net Income | -1.13B KRW |
| Total Assets | 298.38B KRW |
| Net Assets | 125.00B KRW |
| Employees | 509 |
| Value | |
| P/B | 0.67x |
| P/S | 0.53x |
| FCF Yield | -13.01% |
| Profitability | |
| ROE | -0.90% |
| ROA | -0.38% |
| Op. Margin | -2.33% |
| Revenue Growth | -4.29% |
| Earnings Growth | -325.41% |
| Financial Health | |
| Debt Ratio | 138.71% |
| Total Debt | 145.85B KRW |
| FCF | -10.95B KRW |
| Cash | 955.7M KRW |
| Current Ratio | 1.10x |
| Dividend | |
| Div. Yield | 0.63% |
| Div. Growth | -0.00% |
| Performance | |
| 1Y Return | -33.59% |
| 1M Return | -12.69% |
| From 52W High | -44.52% |
| 1Y MDD | -37.96% |
| Trading | |
| Volume | 588,863 shares |
| Foreign Own. | 1.01% |
| Per Share | |
| EPS | -1,060 KRW |
| BPS | 22,785 KRW |
Company Info
Chong Kun Dang Bio was established in 2001 through a spin-off of the fermentation and refined raw materials business. It supplies over 30 types of active pharmaceutical ingredients (APIs), including antibiotics, to over 50 countries worldwide using advanced fermentation facilities. The company produces probiotic raw materials and finished products with its fermentation and patented technologies, and has launched botulinum toxin products from a dedicated plant in Osong. Chong Kun Dang Bio is focusing on obtaining patents for regulatory market entry, achieving cGMP certification for key products, building microbiome CDMO facilities, and developing new drugs for conditions such as Alzheimer's. Chong Kun Dang Bio was established in 2001 and is headquartered in Seodaemun-gu, Seoul.